VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer

Ursula A. Matulonis, MD
Published: Monday, Mar 13, 2017



Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

The NOVA trial started a number of years ago, which examines the oral PARP inhibitor, niraparib, explains Matulonis. Patients partaking in the study had to have platinum-sensitive recurrent ovarian cancer and show responsiveness to the platinum-based agent.

This trial was a 2:1 randomization, which enrolled several hundred patients. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
 


Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

The NOVA trial started a number of years ago, which examines the oral PARP inhibitor, niraparib, explains Matulonis. Patients partaking in the study had to have platinum-sensitive recurrent ovarian cancer and show responsiveness to the platinum-based agent.

This trial was a 2:1 randomization, which enrolled several hundred patients. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x